Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)

Study Overview
=================
Brief Summary
-----------------
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.

Official Title
-----------------
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study

Conditions
-----------------
Stroke, Ischemic, Intravascular Thrombosis, Mechanical Thrombectomy

Intervention / Treatment
-----------------
* Drug: Intra-arterial administration of neuroprotective agents


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years; Acute ischemic stroke patients who is eligible for endovascular treatment; Signed informed consent. Exclusion Criteria: Modified Rankin Score >2 caused by a history of prior stroke; Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (<80000/mm3); Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg); Unsuitable for this clinical studies assessed by researcher.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intra-arterial administration of 3-n-butylphthalide<br>Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min. | Drug: Intra-arterial administration of neuroprotective agents<br>* Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of server adverse events | server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc. | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with modified Rankin Score 0 to 1 | Proportion of patients with modified Rankin Score 0 to 1 | 90 days | 
| Proportion of patients with modified Rankin Score 0 to 2 | Proportion of patients with modified Rankin Score 0 to 2 | 90 days | 
| Modified Rankin Score | Modified Rankin Score | 90 days | 
| Decrease in national institutes of health stroke scale (NIHSS) | Decrease in NIHSS scoring at 48 hours after the treatment | 48 hours | 
| Proportion of symptomatic intracranial hemorrhage (sICH) | sICH was defined as 4 or more increase in NIHSS caused by hemorrhage | 48 hours | 
| Proportion of intraparenchymal hemorrhage (PH1 and PH2) | Proportion of intraparenchymal hemorrhage (PH1 and PH2) within 48 hours after the treatment | 48 hours | 
| Changes in cerebral edema | Cerebral edema was determined by cerebral volume or midline shift | 48 hours |